trending Market Intelligence /marketintelligence/en/news-insights/trending/z6mv84DR0XHt2l91sOUF0w2 content esgSubNav
In This List

Alexion gains license to use Halozyme's drug-delivery technology

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Alexion gains license to use Halozyme's drug-delivery technology

Alexion Pharmaceuticals Inc. entered into a license agreement to use Halozyme Therapeutics Inc.'s Enhanze drug-delivery technology.

Under the terms of the agreement, Alexion may develop up to four targets, including the company's ALXN1210 formulation.

Alexion will pay Halozyme an initial $40 million. The agreement also includes an additional payment of $160 million for each target, subject to specified development, regulatory and sales-based milestones.

Halozyme will also receive royalties on sales of commercialized products.

The Enhanze technology enables a more rapid delivery of injectable medications through subcutaneous injection, which is just under the skin.